Transitional cell carcinoma is a type of cancer that affects the lining of the urinary system, including the bladder, kidneys, and the tubes connecting them. While it can be alarming to face this diagnosis, understanding the treatment landscape—from established therapies to experimental approaches being tested in clinical trials—can help patients and families make informed decisions about their care.

Understanding Your Treatment Path

When transitional cell carcinoma is diagnosed, treatment planning focuses on several important goals. The primary aim is to remove or destroy cancer cells while preserving as much normal organ function as possible. Doctors also work to prevent the cancer from spreading to other parts of the body and to reduce the chance of it coming back after treatment, which is a common concern with this type of cancer. Improving quality of life and managing symptoms are equally important parts of the treatment journey.^[1]

Your treatment will depend heavily on where the cancer is located, how deeply it has grown into the tissue, and whether it has spread beyond its original site. The stage of the cancer—which describes how far it has advanced—plays a crucial role in determining the best approach. Early-stage cancers that are confined to the inner lining often have a much better outlook than those that have grown into deeper layers or spread to lymph nodes or distant organs.^[2]

Your medical team will also consider your overall health, kidney function, age, and personal preferences when recommending treatment options. Because transitional cell carcinoma can occur in different parts of the urinary tract, and because patients who have had it in one location are at higher risk of developing it elsewhere, close monitoring and comprehensive care are essential.^[5]

Standard Treatment Approaches

Surgery remains the cornerstone of treatment for most patients with transitional cell carcinoma of the kidney or ureter. For localized disease that hasn’t spread, the standard approach typically involves complete removal of the affected kidney, the entire ureter, and a small portion of the bladder where the ureter attaches. This procedure, called nephroureterectomy, aims to remove all cancer cells and reduce the risk of recurrence.^[2]

However, not all patients require such extensive surgery. In carefully selected cases—particularly when tumors are small, low-grade, and located in favorable positions—kidney-sparing approaches may be possible. These less invasive procedures use specialized instruments to remove or destroy tumors while preserving kidney function. One such technique is ureteroscopy, where a thin tube with a camera and surgical tools is inserted through the bladder to reach and treat tumors in the ureter or kidney. Surgeons may use lasers, such as holmium or thulium lasers, to destroy cancer tissue during these procedures.^[12]

Kidney-sparing surgery is generally recommended for patients whose tumors meet specific criteria: they must be single tumors rather than multiple growths, measure less than 2 centimeters, appear to be low-grade based on initial biopsies, and show no signs of deep invasion on imaging scans. European medical guidelines strongly support this conservative approach for appropriate candidates, as it can preserve kidney function while still effectively treating the cancer.^[12]

After any kidney-sparing procedure, doctors typically perform a follow-up examination within eight weeks to ensure all cancer has been removed. This careful monitoring is essential because these tumors can recur. In some cases, a percutaneous approach—where instruments are inserted directly through the skin into the kidney—may be used for small tumors in certain locations that are difficult to reach with a ureteroscope.^[12]

For bladder cancer, which represents the most common form of transitional cell carcinoma, treatment often begins with a procedure called transurethral resection. In this operation, the surgeon inserts instruments through the urethra to scrape away or burn off tumors from the bladder lining. This procedure both treats the cancer and provides tissue samples for detailed analysis to determine the tumor’s grade and stage.^[10]

Following transurethral resection of high-grade, non-muscle-invasive bladder cancer, patients typically receive additional therapy delivered directly into the bladder. This intravesical therapy involves placing medication through a catheter into the bladder, where it can act directly on any remaining cancer cells. Two main types of intravesical therapy are used: chemotherapy drugs and immunotherapy with a vaccine called BCG (Bacillus Calmette-Guérin). BCG stimulates the immune system to attack cancer cells and has been a standard treatment for decades.^[10]

When transitional cell carcinoma has invaded the muscle layer of the bladder—a more advanced and aggressive form—treatment typically requires more intensive approaches. The standard recommendation is usually chemotherapy given before surgery, followed by complete removal of the bladder, or alternatively, a combination of chemotherapy and radiation therapy. The choice between these options depends on many factors, including the patient’s overall health and personal preferences about quality of life considerations.^[10]

Chemotherapy in Standard Care

Chemotherapy plays several important roles in treating transitional cell carcinoma. For patients with advanced disease that has spread beyond the primary site or recurred after initial treatment, systemic chemotherapy—medication that travels through the bloodstream to reach cancer cells throughout the body—becomes a central part of treatment.^[9]

The most commonly used chemotherapy regimen is based on cisplatin, a platinum-based drug that has shown effectiveness against transitional cell carcinomas. Cisplatin is typically combined with other chemotherapy drugs in treatment protocols. However, cisplatin can only be used in patients whose kidneys are functioning well enough to process and eliminate the drug safely. This presents a particular challenge in kidney cancer patients, whose kidney function may already be compromised by their disease or by previous surgery.^[12]

For patients whose cancer has invaded the bladder muscle, chemotherapy may be given before surgery in what’s called neoadjuvant therapy. The advantage of this approach is that it allows patients to receive cisplatin-based treatment while they still have two functioning kidneys, before surgery reduces kidney function. Though this strategy makes theoretical sense, large randomized studies specifically in upper tract transitional cell carcinoma haven’t been published yet.^[12]

Adjuvant chemotherapy—given after surgery to eliminate any remaining cancer cells—is generally recommended for select patients who have adequate kidney function. The goal is to reduce the risk of the cancer returning or spreading. The specific chemotherapy regimen, duration of treatment, and timing are all carefully tailored to each patient’s situation.^[12]

Chemotherapy does come with side effects, which can vary depending on the drugs used and the individual patient. Common side effects include nausea, fatigue, increased risk of infection due to low blood counts, hair loss, and numbness or tingling in the hands and feet called peripheral neuropathy. Kidney function must be monitored closely during treatment, particularly with cisplatin-based regimens. Your medical team will work to manage these side effects and adjust treatment if needed.^[5]

Exploring New Treatments in Clinical Trials

While standard treatments form the foundation of care for transitional cell carcinoma, researchers are continuously working to develop new and better therapies. Clinical trials are research studies that test promising new treatments before they become widely available. These studies are conducted in phases, each designed to answer specific questions about safety and effectiveness.

Phase I trials are the first step, primarily focusing on determining whether a new treatment is safe for humans and identifying the appropriate dose. Phase II trials expand testing to a larger group of patients to evaluate whether the treatment actually works against the cancer. Phase III trials compare the new treatment directly with standard therapy to see if it offers better results, fewer side effects, or other advantages.^[2]

Immunotherapy Advances

One of the most promising areas of research in transitional cell carcinoma involves immunotherapy, particularly drugs that work by blocking proteins called immune checkpoints. These proteins normally act as brakes on the immune system, preventing it from attacking the body’s own cells. Cancer cells often exploit these checkpoints to hide from immune attack. Checkpoint inhibitor drugs release these brakes, allowing the immune system to recognize and destroy cancer cells.^[5]

Several checkpoint inhibitors targeting proteins called PD-1 and PD-L1 have been tested in clinical trials for transitional cell carcinoma. These medications have shown particular promise in patients with advanced or metastatic disease who have already received chemotherapy. Some patients have experienced significant tumor shrinkage or disease stabilization with these treatments. The side effects of immunotherapy differ from those of chemotherapy—instead of attacking rapidly dividing cells, immune therapies can cause the immune system to attack normal organs, leading to inflammation in the lungs, colon, liver, or other organs. However, many patients find these side effects more manageable than traditional chemotherapy.^[10]

Researchers are also investigating combinations of different immunotherapy drugs or combinations of immunotherapy with chemotherapy to see if these approaches work better than either treatment alone. These combination strategies are being tested in various clinical trial settings around the world, including in the United States, Europe, and other regions.^[5]

Targeted Therapy Research

Another exciting area involves targeted therapies—drugs designed to attack specific molecular abnormalities found in cancer cells while sparing normal cells. Scientists have identified various genetic changes that occur in transitional cell carcinomas, and they’re developing drugs to target these specific alterations.^[13]

One target of particular interest is the FGFR (fibroblast growth factor receptor) family of proteins. Some transitional cell carcinomas have mutations or other changes in FGFR genes that make the cancer cells dependent on signals from these proteins for growth and survival. FGFR inhibitors are drugs that block these signals, essentially cutting off a survival pathway the cancer needs. These inhibitors are being tested in clinical trials for patients whose tumors have specific FGFR genetic alterations.^[12]

Another targeted approach involves medications that attack a protein called Nectin-4, which is found on the surface of many transitional cell carcinoma cells. Anti-Nectin-4 antibodies can deliver toxic chemotherapy directly to cancer cells that display this protein, potentially making treatment more effective while causing fewer side effects than traditional chemotherapy. These antibody-drug conjugates represent a sophisticated approach to precision cancer medicine.^[12]

Before patients can receive these targeted therapies, their tumors must be tested to see if they have the specific molecular features the drugs target. This personalized approach means that treatment is tailored to the unique characteristics of each person’s cancer, rather than using a one-size-fits-all strategy.

Topical Therapies for Upper Tract Disease

Researchers are also investigating whether topical treatments—medications applied directly to the cancer site—can be used more effectively for transitional cell carcinomas of the kidney and ureter. Similar to how BCG and chemotherapy are instilled into the bladder, scientists are exploring ways to deliver these treatments to the upper urinary tract through catheters or during ureteroscopy procedures. This approach could potentially treat cancer while preserving kidney function in carefully selected patients.^[12]

These topical therapies are generally offered to patients who have low-grade tumors, those with cancer in a single kidney, or those who aren’t healthy enough for major surgery. The goal is to control the cancer while maintaining quality of life and kidney function. Clinical trials are working to determine which patients benefit most from this approach and to optimize the techniques for delivering medication to the upper urinary tract.^[12]

Neoadjuvant and Adjuvant Therapy Studies

Clinical trials are also examining the best timing for various treatments. Questions being investigated include whether giving immunotherapy or targeted therapy before surgery (neoadjuvant) can shrink tumors and improve surgical outcomes, and whether these treatments after surgery (adjuvant) can reduce recurrence rates. Preliminary results from some of these studies have been encouraging, showing improvements in certain clinical parameters or positive safety profiles, but more research is needed to establish which patients benefit most.^[12]

Many of these clinical trials are being conducted at major cancer centers in the United States, Europe, and other regions. Eligibility for trials typically depends on factors such as the stage and grade of cancer, previous treatments received, overall health status, and kidney function. Patients interested in clinical trials should discuss with their healthcare team whether any trials might be appropriate for their situation.^[2]

Most Common Treatment Methods

• Surgery
  • Complete removal of kidney, ureter, and bladder cuff (nephroureterectomy) for localized upper tract disease
  • Kidney-sparing procedures using ureteroscopy with laser ablation for small, low-grade tumors
  • Transurethral resection for bladder tumors to remove cancer and obtain tissue samples
  • Complete bladder removal for muscle-invasive bladder cancer in appropriate cases
• Intravesical Therapy
  • BCG immunotherapy delivered directly into the bladder to stimulate immune response against cancer
  • Chemotherapy medications instilled into the bladder to treat or prevent recurrence of bladder cancer
• Systemic Chemotherapy
  • Cisplatin-based combination regimens for advanced or metastatic disease
  • Neoadjuvant chemotherapy before surgery for muscle-invasive disease
  • Adjuvant chemotherapy after surgery to reduce recurrence risk in select patients
• Immunotherapy
  • Immune checkpoint inhibitors targeting PD-1 or PD-L1 proteins for advanced disease
  • Combinations of different immunotherapy drugs being tested in clinical trials
  • Immunotherapy combined with chemotherapy in research settings
• Targeted Therapy
  • FGFR inhibitors for tumors with specific genetic alterations in FGFR genes
  • Anti-Nectin-4 antibody-drug conjugates that deliver chemotherapy directly to cancer cells
  • Other molecularly targeted drugs being investigated in clinical trials
• Radiation Therapy
  • Combined with chemotherapy as an alternative to bladder removal in some muscle-invasive cases
  • Adjuvant radiation after surgery for high-grade disease to improve local control

Life After Treatment: Surveillance and Quality of Life

Treatment doesn’t end when surgery is complete or chemotherapy finishes. Transitional cell carcinomas have a well-known tendency to recur, making long-term follow-up essential. If you’ve had bladder cancer and were successfully treated, you still face a 30% to 50% chance of developing transitional cell carcinoma in your kidney or ureter later. Similarly, if you had upper tract cancer, your risk of later developing bladder cancer can be as high as 75% if the original cancer involved both the kidney and ureter.^[15]

Your surveillance plan will typically include regular cystoscopy examinations to check your bladder, urine tests to look for cancer cells or blood, and imaging studies such as CT scans to monitor your kidneys and ureters. The frequency of these tests will depend on your individual risk factors, but expect them to be quite frequent in the first few years after treatment, then gradually spacing out if no cancer returns.^[1]

Many survivors experience anxiety about cancer returning. This fear is completely normal and often decreases with time, though it may intensify around the time of surveillance appointments. Staying informed about your disease, understanding your personal risk factors, and maintaining open communication with your healthcare team can help manage this anxiety. Some patients find it helpful to connect with support groups where they can share experiences with others who understand what they’re going through.^[20]

Lifestyle modifications can play a role in reducing recurrence risk. If you smoke, quitting is the single most important step you can take—smoking is thought to cause about half of all bladder cancers and significantly increases risk for all transitional cell carcinomas. Staying well-hydrated by drinking six to eight glasses of water daily may help protect your bladder and remaining kidney. A diet rich in fruits, vegetables, and whole grains provides nutrients that support overall health and may reduce cancer risk. Regular physical activity, even just 30 minutes of moderate exercise daily, can reduce anxiety, improve energy levels, and may lower recurrence risk.^[20]

Fatigue is one of the most common challenges survivors face. This isn’t ordinary tiredness—cancer-related fatigue can be overwhelming and doesn’t improve with rest alone. Paradoxically, gentle exercise often helps more than resting. Other strategies include maintaining good sleep habits, eating nutritious meals, staying hydrated, and being selective about how you spend your energy. Don’t hesitate to ask for help with daily tasks or to adjust your work schedule if needed.^[20]

If you’ve had a kidney removed, you can live a healthy life with one kidney, but you’ll need to take special care of your remaining kidney. This means staying hydrated, avoiding medications that can damage kidneys (such as certain pain medications), keeping blood pressure under control, and having your kidney function checked regularly. Your doctor may recommend adjustments to medication doses since they’ll be processed by a single kidney.^[5]

The Importance of Self-Advocacy and Support

Navigating cancer treatment requires you to become an active participant in your care. Don’t hesitate to ask questions until you fully understand your diagnosis, treatment options, and what to expect. If something your doctor says is unclear, ask for clarification or for the information to be explained in simpler terms. Bring a family member or friend to important appointments—they can help remember details you might miss and provide emotional support.^[22]

Many patients find it helpful to keep a notebook or file with their medical information, including test results, medication lists, and questions for upcoming appointments. This organization helps you feel more in control and ensures important information doesn’t get lost. Some patients also find it valuable to seek a second opinion, particularly for major treatment decisions. Most doctors support this and will provide copies of records for another specialist to review.^[2]

The role of caregivers—usually family members or close friends—cannot be overstated. Surgery and recovery can leave you temporarily unable to care for yourself, drive to appointments, or make complex decisions. Having someone who can help with practical tasks, attend appointments with you, advocate for your needs, and provide emotional support makes an enormous difference. Be aware that caregivers and patients sometimes have different styles of coping—one may want to research everything while the other prefers to take things as they come. Recognizing and respecting these differences can prevent conflicts during an already stressful time.^[22]

Financial concerns often add to the stress of cancer treatment. Don’t wait until bills become overwhelming to seek help. Many hospitals have financial counselors who can help you understand costs, work out payment plans, or connect you with assistance programs. If you’re working, learn about your rights regarding medical leave and whether you qualify for short-term disability benefits. Some employers offer employee assistance programs that can help navigate these issues.^[22]